Ocular Therapeut Stock Price, News & Analysis

Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced that CEO Antony Mattessich will participate in a fireside chat at the Cowen 42nd Annual Healthcare Conference on March 9, 2022, at 9:10 AM EDT. The management team will also hold investor meetings during the event. Interested investors can schedule meetings through their Cowen representatives. A live webcast of the presentation will be available on the company's website. Ocular Therapeutix specializes in innovative therapies for eye conditions, including its FDA-approved product, DEXTENZA, and its ongoing clinical trials for various ophthalmic treatments.

Ocular Therapeutix reported Q4 2021 financial results, highlighting net sales of DEXTENZA® at $12.2 million, a 77% year-over-year increase, despite challenges from the Omicron variant. The establishment of a dedicated business unit for DEXTENZA aims to enhance its market presence. The company also completed enrollment for the U.S. clinical trial of OTX-TKI, with data expected in late 2022. Overall, net loss narrowed to $(3.9 million) from $(85.6 million), reflecting improved financial health.

Ocular Therapeutix, Inc. (Nasdaq: OCUL) will release its fourth quarter and year-end financial results on February 28, 2022, after market close. A live conference call will follow at 4:30 p.m. ET to discuss results and provide business updates. The call can be accessed via their website or through provided phone numbers. The company focuses on innovative eye therapies, including the FDA-approved DEXTENZA®. Their pipeline includes OTX-TKI and OTX-TIC, both in clinical trials for various eye conditions.

Ocular Therapeutix (NASDAQ:OCUL) announced its intention to present data from two Phase 1 clinical trials at upcoming medical meetings. The data on OTX-TKI, an axitinib implant for wet AMD, will be shared at the Angiogenesis Meeting on February 12, 2022. Meanwhile, OTX-TIC, a travoprost implant for glaucoma, will be presented at the Glaucoma360 Meeting on February 11, 2022. The interim data highlighted safety and efficacy, with over 60% of OTX-TKI subjects showing extended activity over six months. The company aims to begin a Phase 2 trial for OTX-TIC soon.

Ocular Therapeutix (NASDAQ:OCUL) has announced the dosing of its first patient in a real-world study in China, evaluating the safety and efficacy of DEXTENZA® (0.4 mg dexamethasone ophthalmic insert) for treating ocular inflammation and pain post-cataract surgery. This trial aims to enroll about 120 patients and assess key endpoints at Days 8 and 14. Ocular entered a licensing agreement with AffaMed Therapeutics in 2020, receiving an upfront payment of $12 million and the potential for up to $91 million in milestone payments. The ophthalmology market in China is valued at $5 billion.

Ocular Therapeutix, Inc. (Nasdaq: OCUL) announced its participation in the H.C. Wainwright BioConnect 2022 Virtual Conference from January 10-13, 2022. The management team will also host virtual investor meetings during the event. A pre-recorded presentation will be available from 7:00 AM ET on January 10 and can be accessed on the Company's investors section of its website, with a replay available for 90 days. Ocular Therapeutix focuses on innovative therapies for eye conditions.

Ocular Therapeutix announced positive topline results from its Phase 2 clinical trial of OTX-DED, a dexamethasone insert for treating dry eye disease. The trial achieved its primary endpoint, showing significant improvement in bulbar conjunctival hyperemia compared to a vehicle insert, with p-values of 0.004 and 0.028 for the 0.2 mg and 0.3 mg formulations, respectively. The studied insert was well tolerated, with no ocular serious adverse events reported. A conference call to discuss the findings is scheduled for 8:00 a.m. ET.

Ocular Therapeutix, Inc. (Nasdaq: OCUL) will participate in two upcoming healthcare conferences: the Jefferies London Healthcare Conference on November 18, 2021, with on-demand access to a pre-recorded fireside chat, and the Piper Sandler 33rd Annual Healthcare Conference starting November 22, 2021. Management will have virtual investor meetings available. Interested investors can view the presentations through the company's website.

Ocular Therapeutix announced that the U.S. Court of Appeals for the Federal Circuit upheld the Patent Trial and Appeal Board's (PTAB) ruling declaring Mati Therapeutics’ patent invalid. This ruling affects the patent related to dexamethasone drug delivery systems, previously claimed to be infringed by Ocular's product, DEXTENZA®. CEO Antony Mattessich expressed satisfaction with the ruling, reinforcing Ocular's commitment to protecting its products. The company holds multiple patents for DEXTENZA, expiring between 2030 and 2040, and continues to believe in the invalidity of any further claims from Mati.